

Version 01 Update: 07/18/2023

Product Manual Pertuzumab Pharmacokinetic ELISA Kit

Cat. No. L00978

For Research Use Only. Not for Use in Diagnostic Procedures.

The operator should read the technical manual carefully before using this product.



Contents

I. DESCRIPTION
II. ASSAY PRINCIPLE
III. ANALYTICAL CHARACTERISTICS
IV. KIT CONTENTS
V. STORAGE
VI. REAGENTS/EQUIPMENT NEEDED BUT NOT SUPPLIED
VII. PRECAUTIONS
VIII. SPECIMEN COLLECTION AND STORAGE
IX. PROTOCOL
Reagent Preparation
• Capture Plate Preparation6
• Test Procedure
X. ASSAY PROCEDURE SUMMARY
XI. ANALYTICAL PERFORMANCE
• Linearity and Limit of Detection
• Precision and Accuracy
• Selectivity
Dilutional Linearity and Hook Effect11
• Specificity
XII. TROUBLESHOOTING
XIII. REFERENCES



I. DESCRIPTION

Pertuzumab, marketed under the brand name Perjeta, is a HER2/neu receptor antagonist. It works by preventing the formation of the HER2/HER3 dimer, which in turn blocks signaling by the dimer. Pertuzumab is used in combination with trastuzumab for the treatment of patients with HER2-positive tumors. It is a humanised IgG1 monoclonal antibody produced in mammalian cells.

GenScript's Pertuzumab Pharmacokinetic ELISA Kit had been comprehensively developed and validated for quantitative measurement of Pertuzumab in cynomolgus monkey serum and plasma, based on the ICH M10 and the FDA bioanalytical method validation guidance for industry. Its precision, accuracy, dilutional linearity, specificity, selectivity, stability, and hook effect were acceptable according to the guidances^[1-4]. The Pertuzumab ELISA kit is a validated tool for whole Pertuzumab and its biosimilar quantification in biological matrices for drug research and development.

II. ASSAY PRINCIPLE

Pertuzumab Pharmacokinetic ELISA Kit is a sandwich ELISA assay with a pair of anti-idiotypic monoclonal capture and detection antibodies. When standards or samples are added to the capture plate, the Pertuzumab in the sample can be captured on the plate coated with the Pertuzumab capture antibody. Then the Biotin Anti-Pertuzumab Antibody is added to interact with the Pertuzumab bound on the plate. Streptavidin-HRP (Streptavidin-Horseradish Peroxidase conjugate) is added to interact with the Biotin Anti-Pertuzumab Antibody. After the washing steps, TMB Solution is added, resulting in the formation of blue color. The reaction is stopped by adding Stop Solution. Adding the Stop Solution changes the color from blue to yellow. The intensity of the color can be read at 450 nm and 630 nm by a microplate reader.

The quantity of Pertuzumab in the sample is precisely quantified against a Pertuzumab standard curve.

Features	Specifications
LLOQ	6.25 ng/mL
ULOQ	400 ng/mL
Intra-assay	CV≤10%
Inter-assay	CV≤15%
Minimum required dilution (MRD)	1:50, validated non-human primate plasma

III. ANALYTICAL CHARACTERISTICS



IV. KIT CONTENTS

The kit provides the following reagents and solutions for the quantitative measurement of Pertuzumab and its biosimilar in biological matrices.

Component	Quantity/Size	Part No.
Capture Plate	1 plate	L1-80
Standard Stock	1 vial (50 μL)	L1-10
100×Biotin Anti-Pertuzumab Antibody	1 vial (160 μL)	L1-20
Streptavidin-HRP	1 bottle (12 mL)	L1-30
Sample Dilution Buffer	1 bottle (60 mL)	L1-60
Assay Dilution Buffer	1 bottle (15 mL)	L1-90
20×Wash Solution	1 bottle (60 mL)	L1-70
Stop Solution	1 bottle (6 mL)	A1-50
TMB Solution	1 bottle (12 mL)	A1-40
Plate Sealer	2 pieces	N/A
User Manual	1 piece	N/A

Table 1.	Components	of the	kit
----------	------------	--------	-----

- Capture Plate: 96 well microplates (8 wells x 12 strips); 12 strips are configured in plate; plate is sealed in a foil pouch with a desiccant.
- Standard Stock contains 40 µg/mL of Pertuzumab.

V. STORAGE

The unopened kit is stable for at least 12 months from the date of manufacture at 2°C to 8°C, and the opened kit is stable for up to 21 days from the date of opening at 2°C to 8°C.

VI. REAGENTS/EQUIPMENT NEEDED BUT NOT SUPPLIED

- Fresh matrix (normal serum or plasma from human or non-human primate)
- Microplate reader capable of measurement at 450 nm with the correction wavelength set at 630 nm
- Data analysis and graphing software. It is recommended to use software which is capable of generating a four-parameter logistic (4-PL) curve-fit
- Automated microplate washer
- Deionized or distilled water
- Graduated cylinder
- Plastic container
- Tubes to aliquot and dilute samples
- 10 μL, 200 μL, and 1000 μL precision pipettes and pipette tips



- Multichannel pipettes
- Disposable reagent reservoir
- Absorbent paper
- Laboratory timer
- Refrigerator
- Centrifuge
- 25 ± 2 °C and 37± 2 °C incubator
- Rotary shaker
- Vortex Mixer

VII. PRECAUTIONS

- All reagents containing human material should be handled as potentially infectious. Operators should wear gloves and protective clothing when handling any patient sera or serum based products.
- 2. Reagents that contain preservatives may be toxic if ingested, inhaled, or spilled on the skin.
- 3. Avoid contact with skin, eyes, or clothing with Stop Solution or TMB Substrate. Keep the container tightly closed. In case of an accident, please seek medical advice immediately.
- 4. Do not use the kit if there is any visible damage to the packaging or kit contents.
- 5. Do not mix components from different batches. Do not mix with components from other manufacturers.
- 6. Do not use reagents beyond the stated expiry date.
- All reagents must be equilibrated to room temperature (20°-25°C) before running the assay. Only take an appropriate amount of reagents at once. Do not put unused reagents back into the vials as reagent contaminations may occur.
- 8. Before opening the Standard Stock, quickly span the vial to ensure that all the liquid has collected at the bottom, and prevent the liquid from splashing when opening the lid.
- 9. Use only distilled or deionized water and clean glassware.
- 10. Do not let wells dry during the test, add reagents immediately after completing washing steps.

VIII. SPECIMEN COLLECTION AND STORAGE

1. The handling and storage information provided here is intended to be used as a general guideline. Sample stability has not been evaluated. When samples need to be stored for a long time, users need to evaluate the stability of the samples. It is the responsibility of the individual laboratory to use all available references and/or its own studies when establishing alternate



stability criteria that meet their needs.

2. Store specimens at -20°C or lower if not tested immediately. Avoid repeated freeze-thaw cycles.

IX. PROTOCOL

• Reagent Preparation

All reagents must be equilibrated to room temperature before use (20°C-25°C). All samples and reagents should be vortexed before use. Store all reagents back in the refrigerator promptly after use.

1× Wash Solution: Dilute the 20× Wash Solution with deionized or distilled water with a volume ratio of 1:19. For example, dilute 40 mL of 20× Wash Solution with 760 mL of deionized or distilled water to make 800 mL of 1× Wash Solution. Store the solution at 2°C to 8°C when not in use.

Note: If any precipitate is found in the 20× Wash Solution, incubate the bottle in a water bath (up to 50°C) with occasional mixing until all the precipitate is dissolved.

1×Biotin Anti-Pertuzumab Antibody: Dilute the 100×Biotin Anti-Pertuzumab Antibody with Assay Dilution Buffer with a volume ratio of 1:99. For example, dilute 120 μ L of 100×Biotin Anti-Pertuzumab Antibody with 11.88 mL of Assay Dilution Buffer to make 12 mL of 1×Biotin Anti-Pertuzumab Antibody. Store the solution at 2°C to 8°C when not in use.

Calibration Standard Preparation: Calibration standards should be prepared with a <u>fresh</u> <u>matrix (The reagents are not provided in the kit)</u> to generate eight Pertuzumab concentrations: fresh matrix (NC), 6.25, 12.5, 25, 50, 100, 200, and 400 ng/mL. Preparation of a whole set of standards is recommended in table 2. S-Int1 preparation is described below as an example.

Standard	Dilution	Source	Source Volume	Matrix Volume	Final Volume	Final Conc.
ID	Factor	Source	voluliie (μL)	voluliie (μL)	volulile (μL)	(ng/mL)
S-Int1	10	Standard Stock (L1-10)	10	90	100	4000
Std1	10	S-Int1	10	90	100	400
Std2	2	Std1	30	30	60	200
Std3	2	Std2	30	30	60	100
Std4	2	Std3	30	30	60	50
Std5	2	Std4	30	30	60	25
Std6	2	Std5	30	30	60	12.5
Std7	2	Std6	30	30	60	6.25
NC	0	/	/	60	60	/

 Table 2. Recommended standard preparation



Quality Control Preparation: QCs should be prepared with <u>fresh matrix</u> to generate five Pertuzumab concentrations: 6.25 (LLOQ), 18.75 (LQC), 75 (MQC), 300 (HQC) and 400 (ULOQ) ng/mL. Preparation of a whole set of standards is recommended in table 3. Q-Int1 preparation is described below as an example.

Note: QC is quality control. LQC is low quality control. MQC is medium quality control. HQC is high quality control. LLOQ is lower limit of quantification. ULOQ is upper limit of quantification.

Q-Int1 preparation: Vortex and centrifuge Standard Stock for several seconds. Dilute Standard Stock with a fresh matrix with a volume ratio of 1:10. For example, add 10 μ L of Standard Stock to 90 μ L of fresh matrix and mix it well to make 100 μ L of Q-Int1.

QC ID	Dilution Factor	Source	Source Volume (μL)	Matrix Volume (μL)	Final Volume (μL)	Final Conc. (ng/mL)
Q-Int1	10	Stock (L1-10)	10	90	100	4000
ULOQ	10	S-Int1	10	90	100	400
HQC	1.3	ULOQ	60	20	80	300
MQC	4	HQC	15	45	60	75
LQC	4	MQC	15	45	60	18.75
LLOQ	3	LQC	20	40	60	6.25

Table 3. Recommended quality control preparation

• Capture Plate Preparation

It is recommended that all standards, quality controls, and samples be prepared in duplicate at least. Table 4 is an example for the setup of Pertuzumab standards and samples.

Count the strips according to the number of test samples and install the strips. Make sure the strips are tightly snapped into the plate frame.

Leave the unused strips in the foil pouch and store at 2°C to 8°C. The strips must be stored in the closed foil pouch to prevent moisture from damaging the Capture Plate.

	1	2	3	4	5	6	7	8	9	10	11	12
Α	Std1	Std1	ULOQ	ULOQ	S4	S4	S12	S12	S20	S20	S28	S28
в	Std2	Std2	HQC	HQC	S5	S5	S13	S13	S21	S21	S29	S29
С	Std3	Std3	MQC	MQC	S6	S6	S14	S14	S22	S22	S30	S30
D	Std4	Std4	LQC	LQC	S7	S7	S15	S15	S23	S23	S31	S31
E	Std5	Std5	LLOQ	LLOQ	S8	S8	S16	S16	S24	S24	S32	S32
F	Std6	Std6	S1	S1	S9	S9	S17	S17	S25	S25	S33	S33
G	Std7	Std7	S2	S2	S10	S10	S18	S18	S26	S26	S34	S34
н	NC	NC	S3	S3	S11	S11	S19	S19	S27	S27	S35	S35

Table 4. Setup of standards, quality controls and samples on Capture Plate

S: Sample number



Test Procedure

Standards and Samples Incubation

- Dilute standards, QCs and samples with <u>Sample Dilution Buffer</u> with a volume ratio of 1:50.
 Note: Both standards and QCs are working solutions that have been diluted in the matrix, see PROTOCOL.Reagent Preparation for step details.
- 2. Add 100 μ L of the diluted standard solutions, controls and samples to the corresponding wells in the Capture Plate.
- 3. Cover the plate with Plate Sealer and incubate at 37°C for 60 minutes.
- 4. Remove the Plate Sealer and wash the plate with 260 μL of 1× Wash Solution five times.
- 5. Tap the inverted plate onto absorbent paper to remove residual liquid in the wells after the wash steps.

Detection Antibody Incubation

- 6. Add 100 μ L of 1× Biotin Anti-Pertuzumab Antibody to all the testing wells.
- 7. Cover the plate with Plate Sealer and incubate at 37°C for 30 minutes.
- 8. Remove the Plate Sealer and wash the plate with 260 μ L of 1× Wash Solution five times.
- 9. Tap the inverted plate onto absorbent paper to remove residual liquid in the wells after the wash steps.

Enzyme Conjugate Incubation

- 10. Add 100 μ L of Streptavidin-HRP to all the testing wells.
- 11. Cover the Plate with Plate Sealer and incubate at 37°C for 10 minutes.
- 12. Remove the Plate Sealer and wash the plate with 260 μ L of 1× Wash Solution five times.
- 13. Tap the inverted plate onto absorbent paper to remove residual liquid in the wells after the wash steps.

Absorbance Measurement and Calculation


 Add 100 μL of TMB Solution to each well and incubate the plate in the dark at 25°C for 15 minutes (start timing after the addition of TMB Solution to the first well).

Note: TMB incubation time could extend to 20 minutes based on test signals.

- 15. Add 50 μL of Stop Solution to each well to stop the reaction.
- 16. Read the absorbance in the microplate reader at 450 nm against 630 nm as a reference filter.
- 17. Plot the standard curve with the Pertuzumab concentration (ng/mL) on the x-axis and the corresponding mean absorbance value on the y-axis.
- 18. Using a 4- or 5-parameter logistic curve fitting program, calculate the best-fitting linear line through the points of the standard curve.



X. ASSAY PROCEDURE SUMMARY





XI. ANALYTICAL PERFORMANCE

• Linearity and Limit of Detection

A set of Pertuzumab calibration standards were freshly prepared and analyzed. Standard curves were constructed using a four- or five-parameter logistic curve. The typical dynamic range of the kit is 6.25-400 ng/mL (0.125-8 ng/mL diluted) and its detection limit is 6.25 ng/mL (Table 5 & Figure 1).

Pertuzumab	Absorba	nce (OD 450/63	30nm)	Measured	cv	Accuracy
(ng/mL)			Average	Pertuzumab (ng/mL)	%	Accuracy %
400	2.499	2.421	2.460	399.96	2.2	100.0
200	1.264	1.362	1.313	200.44	5.3	100.2
100	0.674	0.658	0.666	99.06	1.7	99.1
50	0.342	0.348	0.345	50.80	1.1	101.6
25	0.171	0.175	0.173	25.16	1.7	100.6
12.5	0.086	0.088	0.087	12.23	2.1	97.8
6.25	0.044	0.050	0.047	6.11	8.5	97.8
N/A	0.009	0.008	0.008	/	3.4	/

Table F	Samplo	data	for	standard curve
lable 5.	Sample	data	TOP	standard curve

Pertuzumab Standard Curve




Figure 1: Pertuzumab ELISA kit standard curve.

A set of Pertuzumab calibration standards from 400 ng/mL to 6.25 ng/mL was then diluted with Sample Dilution Buffer with a volume ratio of 1:50.



• Precision and Accuracy

Pertuzumab Quality Controls at three concentrations (HQC of 300 ng/mL, MQC of 75 ng/mL, and LQC of 18.75 ng/mL) were tested for precision and accuracy in three batches of the kits, with each sample tested three times.

	Dortuzu	Intra-a	assay (n=	10)	Inter-assay (n=30)		
Quality Control	Pertuzu mab (ng/mL)	Measured Pertuzumab (ng/mL)	CV %	Accuracy %	Measured Pertuzumab (ng/mL)	CV %	Accuracy %
HQC	300	279.02	5.7	93.0	279.12	4.5	93.0
MQC	75	74.01	3.6	98.7	74.50	4.3	99.3
LQC	18.75	19.73	4.3	105.2	21.09	12.9	112.5

Table 6. Intra-assay and inter-assay precision and accuracy of the kit

• Selectivity

Selectivity was tested by spiking plasma of ten different samples from non-human primate with Pertuzumab Quality Controls at two concentrations (HQC of 300 ng/mL and LLOQ of 6.25 ng/mL). Based on the ICH M10 guidance, the mean accuracy for LLOQ was required to be within 75%-125% of the low spiked concentration in at least 90% of the evaluated matrices. The mean accuracy for HQC was required to be within 80%-120% of the high spiked concentration in at least 100% of the evaluated matrices (Table 7).

Table 7. Selectivity analysis of the Kit

H	IQC-Selectivity		LLOQ-Selectivity			
Measured			Measured			
Pertuzumab	CV%	Accuracy%	Pertuzumab	CV%	Accuracy%	
(ng/mL)			(ng/mL)			
304.62	1.5	101.5	5.14	1.2	82.2	
296.90	5.3	99.0	5.07	6.3	81.1	
285.26	2.1	95.1	4.69	1.9	75.0	
293.24	0.2	97.7	4.70	5.2	75.2	
294.98	1.1	98.3	5.70	4.4	91.2	
309.41	0.7	103.1	5.66	0.8	90.6	
305.39	5.6	101.8	5.76	1.7	92.2	
315.36	3.0	105.1	5.37	5.6	85.9	
284.85	4.8	95.0	5.15	19.5	82.4	
277.20	8.5	92.4	4.63	5.1	74.1	



• Dilutional Linearity and Hook Effect

Samples with high concentrations of Pertuzumab were used for the assessment of dilutional linearity (Table 9). The presence of a hook effect was investigated simultaneously. The hook effect was not observed in the assayed range (Table 8).

Pertuzumab	Abs	CV%		
(ng/mL)	Duplicate 1	Duplicate 2	Average	••••
20000	5.90	5.90	5.895	0.0
2000	5.91	5.30	5.604	7.7
1000	4.10	4.19	4.146	1.6

Table 8. Hook effect analysis of the kit

Table 9. Dilutional linearity analysis of the kit

Dilution Factor	Expected Pertuzumab (ng/mL)	Measured Pertuzumab (ng/mL)	CV%	Accuracy%
1000	20	19.04	7.4	95.2
2000	10	10.56	4.6	105.6
100	20	18.74	4.9	93.7
50	20	19.60	8.1	98.0

• Specificity

Pertuzumab QC samples at two concentrations (ULOQ of 400 ng/mL and LLOQ of 6.25 ng/mL) were spiked with different amounts of human IgG1 (800 and 8000 ng/mL). The test result demonstrated that the high concentration of human IgG1 did not interfere with the detection of Pertuzumab (Table 10).

Pertuzumab (ng/mL)	Human lgG1 (ng/mL)	Measured Pertuzumab (ng/mL)	CV%	Accuracy%		
400	4000	380.78	5.6	95.2		
400	400	379.27	1.2	94.8		
6.25	4000	7.80	2.0	124.8		
6.25	400	7.74	3.4	123.8		

Table 10. Specificity analysis of the kit



XII. TROUBLESHOOTING

Problem	Probable Cause	Solution	
Poor Precision	Wells are not washed or aspirated properly	Make sure the washing apparatus works properly and wells are dry after aspiration	
	Wells are scratched with pipette tips or washing needles	Dispense and aspirate solution into and out of wells with caution	
	Particulates are found in the samples	Remove any particulates by centrifugation prior to the assay	
Weak/No Signal	Substrate is not added or added at the wrong time	Follow the manual to add the substrate properly	
	Components are used from other lots or sources	Use only lot-specific components	
	Substrate is contaminated	Use a new substrate from the same Lot	
	Volumes of reagents are not correct	Repeat the assay with the required volumes as noted in the manual	
	The plate is not incubated for proper time or temperature	Follow the manual to repeat the assay	
	The plate is not read within the specified time range	Read the plate within 5 minutes	
High Background	Plate is not washed properly	Make sure the washing apparatus works properly	
	Substrate is contaminated	Use new substrate from the same Lot	
	Evaporation of wells during incubations	Perform incubation steps with a plate sealer in a repeat assay	
	Incorrect incubation times and/or temperatures	Follow the manual to repeat the assay	



XIII. REFERENCES

 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline, Bioanalytical Method Validation M10 (2019).
 www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m10-

bioanalytical-method-validation-step-2b en.pdf

- US FDA. Bioanalytical Method Validation Guidance for Industry (2018).
 www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf
- European Medicines Agency. Guideline on Bioanalytical Method Validation (2011).
 www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation en.pdf
- 4. DeSilva B, Smith W, Weiner R et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support

pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885–1900 (2003).

For research use only. Not intended for human and animal therapeutic or diagnostic use.

生产商:南京金斯瑞生物科技有限公司 江苏省南京市江宁区科学园雍熙路 28 号

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28 Yongxi Road, Jiangning District, Nanjing, Jiangsu, China